Download Download flyer

Approved March 24, 2015
A Research Study to determine whether an investigational drug called Dasotraline is safe
and effective to treat symptoms of Attention-Deficit/Hyperactivity Disorder
This research study is being conducted by Kennedy Krieger Institute/centers across the United
States to determine the efficacy and safety of Dasotraline in male and female adults with
Attention-Deficit Hyperactivity-Disorder (ADHD). If eligible, the participant will visit the
Kennedy Krieger Institute up to 9 times over a period of 13weeks. Each visit will take about 2 to
4 hours and will include psychological and behavioral testing, medical history, physical
examination, blood draws, vital sign, ECG, urine drug screen, and pregnancy testing for females.
For each completed visit, participants will receive a reimbursement of $50.00 for their time and
travel expenses. Please ask a study team member for specifics. All testing is done free of
charge. For more information about this research study, please contact Victoria Osasah at (443)
923-3850 or by email at [email protected]
PI: Robert Findling, M.D., M.B.A.
Johns Hopkins Medicine-IRB No. – IRB00052924
ClinicalTrials.gov No. NCT02160262
Study Sponsor: Sunovion Pharmaceuticals